Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

Beumer JH, Eiseman JL, Gilbert JA, Holleran JL, Yellow-Duke AE, Clausen DM, D'Argenio DZ, Ames MM, Hershberger PA, Parise RA, Bai L, Covey JM, Egorin MJ.

Cancer Chemother Pharmacol. 2011 Feb;67(2):421-30. doi: 10.1007/s00280-010-1337-6.

2.

Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

Beumer JH, Eiseman JL, Parise RA, Florian JA Jr, Joseph E, D'Argenio DZ, Parker RS, Kay B, Covey JM, Egorin MJ.

Cancer Chemother Pharmacol. 2008 Aug;62(3):457-64.

3.

Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.

Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, Egorin MJ.

Clin Cancer Res. 2008 Jun 1;14(11):3529-35. doi: 10.1158/1078-0432.CCR-07-4885.

4.

Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.

Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM, Doroshow JH, Kummar S, Covey JM, Davis M, Eiseman JL.

Cancer Chemother Pharmacol. 2015 Oct;76(4):803-11. doi: 10.1007/s00280-015-2857-x.

5.

Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.

Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ.

Clin Cancer Res. 2006 Dec 15;12(24):7483-91.

6.
7.

Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.

Besnard T, Renée N, Etienne-Grimaldi MC, François E, Milano G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):117-20. doi: 10.1016/j.jchromb.2008.05.040.

PMID:
18562256
8.

Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, Negrotto S, Smith N, Terse P, Engelke KJ, Covey J, Chan KK, Desimone J, Saunthararajah Y.

Blood. 2012 Feb 2;119(5):1240-7. doi: 10.1182/blood-2011-08-371690.

9.

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ.

Cancer Chemother Pharmacol. 2008 Jul;62(2):363-8.

PMID:
17899082
10.

Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.

Kreis W, Woodcock TM, Gordon CS, Krakoff IH.

Cancer Treat Rep. 1977 Oct;61(7):1347-53.

PMID:
589600
11.

Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.

Xiang TX, Niemi R, Bummer P, Anderson BD.

J Pharm Sci. 2003 Oct;92(10):2027-39.

PMID:
14502542
12.

Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.

Terse P, Engelke K, Chan K, Ling Y, Sharpnack D, Saunthararajah Y, Covey JM.

Int J Toxicol. 2014 Mar-Apr;33(2):75-85. doi: 10.1177/1091581814524994.

13.

Analytical and pharmacokinetic studies with 5-chloro-2'-deoxycytidine.

Hale JT, Bigelow JC, Mathews LA, McCormack JJ.

Biochem Pharmacol. 2002 Nov 15;64(10):1493-502.

PMID:
12417262
14.

Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination.

Guo D, Myrdal PB, Karlage KL, O'Connell SP, Wissinger TJ, Tabibi SE, Yalkowsky SH.

AAPS PharmSciTech. 2010 Mar;11(1):247-52. doi: 10.1208/s12249-010-9383-2.

15.

Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.

Funamizu N, Lacy CR, Fujita K, Furukawa K, Misawa T, Yanaga K, Manome Y.

PLoS One. 2012;7(5):e37424. doi: 10.1371/journal.pone.0037424.

16.

Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.

Riccardi R, Chabner B, Glaubiger DL, Wood J, Poplack DG.

Cancer Res. 1982 May;42(5):1736-9.

17.

Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.

Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T.

J Med Chem. 2014 Mar 27;57(6):2582-8. doi: 10.1021/jm401856k.

PMID:
24520856
19.

Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.

Kreis W, Hession C, Soricelli A, Scully K.

Cancer Treat Rep. 1977 Oct;61(7):1355-64.

PMID:
589601
20.

Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.

Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, Eiseman JL.

Cancer Chemother Pharmacol. 2002 Jan;49(1):7-19.

PMID:
11855755
Items per page

Supplemental Content

Support Center